Vaxcyte, Inc. (PCVX): who owns it and who trades it
As of Nov 16, 2026, PCVX insiders reported 60 open-market sales worth $13.8M and no purchases in the last 12 months, with 90% of the sale value made under pre-set 10b5-1 plans. The largest seller was Grant Pickering (CEO), with $3.6M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Vaxcyte
From the latest filingsOverall: about as much buying as selling. Insiders and famous investors mostly sold. Congress mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PCVX
327 funds and institutions reported PCVX shares worth $9.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 14.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 20.85M | 14.44% | $1.2B | +26% |
| Jupiter Topco LLC | 17.97M | 12.44% | $1B | – |
| T. Rowe Price Investment Management, Inc. | 12.21M | 8.45% | $710M | +1% |
| BlackRock, Inc. | 12.07M | 8.36% | $702M | +10% |
| Ra Capital Management, L.P. | 11.47M | 7.95% | $667M | No change |
| Wellington Management Group LLP | 7.00M | 4.85% | $407M | +25% |
| Vanguard Portfolio Management LLC | 6.59M | 4.57% | $383M | +5% |
| Vanguard Capital Management LLC | 6.35M | 4.40% | $369M | +1% |
| State Street Corp | 5.35M | 3.71% | $311M | +21% |
| Deep Track Capital, LP | 4.30M | 2.98% | $250M | No change |
| Geode Capital Management, LLC | 3.46M | 2.40% | $201M | +8% |
| T. Rowe Price Associates | 2.99M | 2.07% | $174M | +206% |
| Kynam Capital Management, LP | 2.92M | 2.02% | $170M | No change |
| Westfield Capital Management Co LP | 2.47M | 1.71% | $144M | -32% |
| Caligan Partners LP | 2.19M | 1.52% | $127M | +6% |
| Paradigm Biocapital Advisors LP | 2.13M | 1.47% | $124M | -56% |
| Bellevue Group AG | 1.97M | 1.37% | $115M | +66% |
| D. E. Shaw & Co., Inc. | 1.90M | 1.32% | $111M | -34% |
| Maverick Capital Ltd | 1.61M | 1.12% | $93.8M | +17% |
| Charles Schwab Investment Management Inc | 1.46M | 1.01% | $85.1M | +4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PCVX insiders reported $0 of open-market purchases and $13.8M of sales. 90% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Harpreet S. Dhaliwal | Chief Technical Ops Offi | Sale plan | 7,135 | $67.33 | $480K | Form 4 |
| Nov 11, 2026 | Harpreet S. Dhaliwal | Chief Technical Ops Offi | Sale plan | 9,345 | $68.16 | $637K | Form 4 |
| Nov 11, 2026 | Harpreet S. Dhaliwal | Chief Technical Ops Offi | Sale plan | 520 | $68.82 | $35.8K | Form 4 |
| Nov 2, 2026 | Elvia Cowan | Vice president | Sale plan | 2,414 | $60.77 | $147K | Form 4 |
| Nov 2, 2026 | Elvia Cowan | Vice president | Sale plan | 586 | $61.55 | $36.1K | Form 4 |
| Nov 2, 2026 | Jim Wassil | Vice president | Sale plan | 1,907 | $60.78 | $116K | Form 4 |
| Nov 2, 2026 | Jim Wassil | Vice president | Sale plan | 343 | $61.57 | $21.1K | Form 4 |
| Oct 5, 2026 | Elvia Cowan | Vice president | Sale plan | 19,000 | $86.74 | $1.6M | Form 4 |
| Oct 5, 2026 | Jim Wassil | Vice president | Sale plan | 18,000 | $86.74 | $1.6M | Form 4 |
| Oct 1, 2026 | Jim Wassil | Vice president | Sale plan | 2,155 | $56.65 | $122K | Form 4 |
| Oct 1, 2026 | Jim Wassil | Vice president | Sale plan | 95 | $57.09 | $5.4K | Form 4 |
| Sep 9, 2026 | Jim Wassil | Vice president | Sale | 1,334 | $59.52 | $79.4K | Form 4 |
| Sep 4, 2026 | Jim Wassil | Vice president | Sale | 1,381 | $61.16 | $84.5K | Form 4 |
| Sep 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 303 | $61.42 | $18.6K | Form 4 |
| Sep 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 1,537 | $60.89 | $93.6K | Form 4 |
| Sep 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 713 | $61.48 | $43.8K | Form 4 |
| Sep 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale | 924 | $60.96 | $56.3K | Form 4 |
| Aug 5, 2026 | Harpreet S. Dhaliwal | Chief Technical Ops Offi | Sale plan | 17,000 | $55.00 | $935K | Form 4 |
| Aug 3, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 861 | $53.50 | $46.1K | Form 4 |
| Aug 3, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 1,389 | $54.09 | $75.1K | Form 4 |
| Aug 3, 2026 | Andrew Guggenhime | CFO | Sale plan | 6,956 | $53.76 | $374K | Form 4 |
| Aug 3, 2026 | Andrew Guggenhime | CFO | Sale plan | 3,044 | $54.18 | $165K | Form 4 |
| Jul 27, 2026 | Grant Pickering | CEO | Sale plan | 622 | $55.54 | $34.5K | Form 4 |
| Jul 27, 2026 | Grant Pickering | CEO | Sale plan | 244 | $55.96 | $13.7K | Form 4 |
| Jul 27, 2026 | Grant Pickering | CEO | Sale plan | 756 | $55.52 | $42K | Form 4 |
| Jul 27, 2026 | Grant Pickering | CEO | Sale plan | 4,415 | $55.93 | $247K | Form 4 |
| Jul 27, 2026 | Grant Pickering | CEO | Sale plan | 11,783 | $55.52 | $654K | Form 4 |
| Jul 27, 2026 | Grant Pickering | CEO | Sale plan | 378 | $55.91 | $21.1K | Form 4 |
| Jul 6, 2026 | Andrew Guggenhime | CFO | Sale plan | 2,087 | $57.76 | $121K | Form 4 |
| Jul 6, 2026 | Andrew Guggenhime | CFO | Sale plan | 7,913 | $57.16 | $452K | Form 4 |
| Jul 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 6 | $57.82 | $347 | Form 4 |
| Jul 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 456 | $57.47 | $26.2K | Form 4 |
| Jul 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 1,788 | $56.03 | $100K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 207 | $54.22 | $11.2K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 602 | $55.30 | $33.3K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 191 | $56.27 | $10.7K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 6,683 | $54.28 | $363K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 9,137 | $55.27 | $505K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 6,417 | $56.12 | $360K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 312 | $54.35 | $17K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 356 | $55.23 | $19.7K | Form 4 |
| Jun 26, 2026 | Grant Pickering | CEO | Sale plan | 332 | $55.99 | $18.6K | Form 4 |
| Jun 18, 2026 | Grant Pickering | CEO | Sale plan | 22,236 | $52.50 | $1.2M | Form 4 |
| Jun 18, 2026 | Grant Pickering | CEO | Sale plan | 225 | $52.51 | $11.8K | Form 4 |
| Jun 18, 2026 | Grant Pickering | CEO | Sale plan | 1,000 | $52.50 | $52.5K | Form 4 |
| Jun 18, 2026 | Andrew Guggenhime | CFO | Sale plan | 10,000 | $53.00 | $530K | Form 4 |
| Jun 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 1,949 | $49.40 | $96.3K | Form 4 |
| Jun 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 301 | $50.26 | $15.1K | Form 4 |
| May 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 2,250 | $56.83 | $128K | Form 4 |
| Apr 7, 2026 | Elvia Cowan | Vice president | Sale plan | 3,000 | $60.00 | $180K | Form 4 |
| Apr 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 838 | $58.93 | $49.4K | Form 4 |
| Apr 1, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 1,412 | $58.14 | $82.1K | Form 4 |
| Mar 17, 2026 | Elvia Cowan | Vice president | Sale plan | 405 | $56.26 | $22.8K | Form 4 |
| Mar 17, 2026 | Elvia Cowan | Vice president | Sale plan | 1,487 | $55.39 | $82.4K | Form 4 |
| Mar 11, 2026 | Elvia Cowan | Vice president | Sale plan | 2,500 | $58.59 | $146K | Form 4 |
| Mar 10, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 4,968 | $59.16 | $294K | Form 4 |
| Mar 10, 2026 | Jim Wassil | CHIEF OPERATING OFFICER | Sale plan | 2,427 | $58.32 | $142K | Form 4 |
| Dec 31, 2025 | Harpreet S. Dhaliwal | Chief Technical Ops Offi | Sale | 9,743 | $46.69 | $455K | Form 4 |
| Dec 23, 2025 | Elvia Cowan | Vice president | Sale | 6,716 | $47.94 | $322K | Form 4 |
| Dec 23, 2025 | Elvia Cowan | Vice president | Sale | 4,907 | $47.90 | $235K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER, Director | – | $3.6M | Jul 27, 2026 |
| Jim Wassil | CHIEF OPERATING OFFICER | – | $3.3M | Nov 2, 2026 |
| Elvia Cowan | SVP, FINANCE | – | $2.8M | Nov 2, 2026 |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | – | $2.5M | Nov 11, 2026 |
| Andrew Guggenhime | PRESIDENT AND CFO | – | $1.6M | Aug 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PCVX short interest
High short interest. 10.3% of PCVX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 15.36M PCVX shares were sold short, 10.3% of the shares outstanding, up 5.0% from the report before. At the average daily volume of 2.28M shares, buying them all back would take about 6.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 15.36M | 10.32% | +5% | 2.28M | 6.7 |
| Oct 15, 2026 | 14.62M | 9.83% | -15% | 5.05M | 2.9 |
| Sep 30, 2026 | 17.29M | 11.62% | +7% | 1.52M | 11.4 |
| Sep 15, 2026 | 16.13M | 10.84% | +7% | 1.24M | 13.0 |
| Aug 31, 2026 | 15.02M | 10.09% | +1% | 947,052 | 15.9 |
| Aug 14, 2026 | 14.80M | 9.94% | +2% | 933,368 | 15.8 |
| Jul 31, 2026 | 14.46M | 10.02% | +2% | 976,182 | 14.8 |
| Jul 15, 2026 | 14.23M | 9.86% | -19% | 1.15M | 12.4 |
| Jun 30, 2026 | 17.47M | 12.10% | +19% | 2.53M | 6.9 |
| Jun 15, 2026 | 14.63M | 10.13% | +1% | 1.36M | 10.7 |
| May 29, 2026 | 14.47M | 10.02% | +5% | 1.64M | 8.8 |
| May 15, 2026 | 13.79M | 9.55% | -3% | 1.78M | 7.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded PCVX
Since Nov 17, 2024, 2 members of Congress reported 6 purchases and 1 sale of PCVX. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Jul 16, 2026, reported Sep 4, 2026.
Purchases 6Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 4, 2026 | Report |
| May 13, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| May 12, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jun 8, 2026 | Report |
| Apr 28, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 15, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 14, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Mar 5, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Apr 11, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Vaxcyte company events
Vaxcyte filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 9, 2026AgreementVaxcyte, Inc. consummated the sale and issuance of $575 million of its 1.50% Convertible Senior Notes due 2032 to certain underwriters. Filing
- Oct 5, 2026AnnouncementThe Company also made available the slide presentation attached as Exhibit 99.2 to this Current Report on Form 8-K, which is incorporated herein by reference. Filing
- Sep 3, 2026LeadershipVaxcyte, Inc. appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 15, 2026LeadershipHeath Lukatch notified the Board of Directors of Vaxcyte, Inc. of his retirement from the Board, effective as of July 16, 2026. Filing
- Jun 23, 2026LeadershipJacks Lee notified the Board of Directors of Vaxcyte, Inc. of his retirement from the Board, effective as of June 17, 2026. Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Feb 24, 2026AnnouncementVaxcyte, Inc. entered into a sales agreement with Leerink Partners LLC, pursuant to which the Company may sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $500 million, from time to time through the Placement Agent. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Feb 2, 2026AnnouncementVaxcyte, Inc. entered into an underwriting agreement with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein, relating to the issuance and sale of 11,000,000 shares of its common stock, par value $0.001… Filing
- Dec 19, 2025LeadershipVaxcyte, Inc. amended existing Executive Change in Control and Severance Agreements with (i) Grant Pickering, Chief Executive Officer and member of the Company’s Board of Directors, dated as of June 12, 2020, (ii) Andrew Guggenhime, President and Chief Financial Officer, dated as of June 12, 2020… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Vaxcyte financials
Famous investors that hold PCVX
4 of the 50 well-known investors we track reported holding PCVX in their latest 13F filing. The largest position is Lee Ainslie's, worth $77.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | Q3 2026 | 1.36M | $77.4M | 0.6% | -16% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 154,204 | $8.8M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 67,027 | $3.8M | 0.0% | -51% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 40,377 | $2.3M | 0.0% | -20% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named PCVX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.2% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.2% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 9.6% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 11.6% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 9.6% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 11.6% |
Questions about Vaxcyte, Inc. (PCVX) stock
Who owns the most PCVX stock?
The largest reported owner of Vaxcyte, Inc. (PCVX) is FMR LLC (Fidelity), with 14.4% of the company. In total, 327 funds and institutions reported holding PCVX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are PCVX insiders buying or selling?
In the last 12 months, PCVX insiders reported no open-market purchases and 60 sales worth $13.8M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in PCVX?
As of Oct 30, 2026, 15.36M PCVX shares were sold short, 10.3% of the shares outstanding, up 5.0% from the report before. At the average daily volume of 2.28M shares, buying them all back would take about 6.7 trading days (days to cover). See the history.
Have members of Congress traded PCVX?
Yes. 2 members of Congress reported 6 purchases and 1 sale of PCVX since Nov 17, 2024. The latest was reported on Sep 4, 2026. See the trades.
Which famous investors hold PCVX?
4 of the 50 well-known investors we track reported PCVX in their latest 13F filing, including Lee Ainslie, Ken Griffin, Israel Englander. The largest position is worth $77.4M. See all holders.
Executive pay
Vaxcyte's chief executive was paid a total of $14.5M for the year ended Dec 31, 2025, down 64% from $39.6M the year before. In the last 12 months, Vaxcyte's executives and directors bought no stock on the open market and sold $13.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.